Clinical Trials Logo

RET-positive Thyroid Cancer clinical trials

View clinical trials related to RET-positive Thyroid Cancer.

Filter by:
  • None
  • Page 1

NCT ID: NCT03131206 Terminated - Clinical trials for RET-positive Non-small Cell Lung Cancer (NSCLC)

A Study of Alectinib in RET-rearranged Non-small Cell Lung Cancer or RET-mutated Thyroid Cancer

Start date: June 19, 2017
Phase: Phase 1/Phase 2
Study type: Interventional

This research trial is studying a drug called alectinib as a possible treatment for non-small cell lung cancer (NSCLC) with specific genetic alterations known as ALK or RET rearrangements, and thyroid cancer with RET rearrangements.